Comprehensive genomic analyses have identified commonly mutated oncogenes and onco-suppressors in pancreatic cancers, such as KRAS proto-oncogene, GTPase (KRAS), cyclin dependent kinase inhibitor 2A (CDKN2A), tumor protein p53 (TP53) and SMAD family member 4 (SMAD4), but none of them is clinically targetable with currently approved therapeutic regimens. The gene discussed is CDKN2A; the disease is familial pancreatic carcinoma.